BackgroundPsoriasis is a chronic inflammatory disorder, characterized by increased
keratinocyte proliferation due to abnormal differentiation of basal
keratinocytes. The etiology of the disease is unclear, and according to the
survey results, it is hypothesized that a combination of genetic and
environmental factors prompts an abnormal immune response in patients with
psoriasis. CD4+ Th cells play a multifaceted role in both immune defense and
pathogenesis of certain diseases such as psoriasis. Nonetheless, the exact
contribution of different subpopulations of Th cells in psoriasis is still
not clear. ObjectiveThe aim of present study was to determine the mRNA expression level of RORC
as potential inducer of Th17 cell differentiation and expression pattern of
Th17-signature cytokines (IL-17A and IL-22).MethodsTwenty patients with psoriasis and twenty-one healthy subjects were included
in the study. Peripheral blood mononuclear cells (PBMCs) were separated and
expression of three genes were determined by quantitative real-time reverse
transcriptase PCR (qRT-PCR). Plasma levels of IL-17 and IL-22 were also
evaluated by ELISA.ResultsRORC, IL-17A and IL-22 gene expression was significantly higher in patients
with psoriasis compared with healthy controls (P<0.05). In addition, a
marked increase in plasma IL-17A and IL-22 levels was observed in patient
group compared to controls (P<0.001).Study limitationssmall number of patients.ConclusionThese data suggest that Th17 response may contribute to the pathogenesis of
psoriasis.
The hepatitis C virus infection represents an important public health problem and is associated with various hepatic and extrahepatic manifestations. Symptoms outside of the liver can occur in multiple organ systems, including hematologic, renal, dermatologic, endocrine, and rheumatologic systems. Among these different organ systems, special attention has focused on the endocrine system because it affects almost every organ in the body. Among the endocrine disorders, thyroid problems are the most common and the thyroid is one of the principal target organs for extrahepatic manifestations in HCV infected patients. In addition, research data suggest that interferon treatment may be associated with immune-mediated thyroid lesions. However, case reports suggest that the response of thyroid extrahepatic manifestations to interferon in patients with chronic HCV is greatly different. The objective of this study was to summarize currently available data on thyroid conditions associated with chronic HCV infection. Moreover, we investigate the incidence of the development of immune mediated thyroid disorders during interferon therapy in these patients.
Background/Aims: Dysregulation of T cell response is thought to play an important role in the immunopathogenesis of autoimmune hepatitis. However, no consensus has yet been reached regarding the implications of a distinct T cell subset in the pathogenesis of this progressive liver disease. Therefore, T-bet and GATA-3 expression was examined in patients with autoimmune hepatitis (AIH) and in healthy controls. Moreover, the profile of Th1 (IFN-γ) and Th2 (IL-4) cytokine gene expression was analyzed. Materials and Methods: Levels of mRNA transcripts were measured in peripheral blood mononuclear cells (PBMCs) using a two-step reverse transcription quantitative real-time polymerase chain reaction with SYBR Green. Results: T-bet and IFN-γ mRNA expression was significantly higher in AIH patients compared to healthy controls (p<0.05), whereas no differences were observed for either GATA-3 or IL-4 mRNA expression (p>0.05). Conclusion: Alterations in the Th1/Th2 cell balance may be responsible for both disease progression and the resulting complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.